Browse recent medication, recall, and health-related stories.
Page 9 of 51
An OU researcher is developing a remote fall risk assessment designed to help caregivers identify fall risks earlier in older adults with Alzheimer’s disease.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
The source of the Legionnaires' disease cluster in the South Bronx has been eliminated, New York City health officials said Wednesday.
The FDA announced a recall of Lior Cinnamon Ground Seasoning sold in six states due to elevated lead levels. Here’s how to identify it.
More than 25,000 of bottles of the diuretic chlorthalidone have been recalled for improper dissolution. Here's what to know.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
One of the major challenges in treating the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance to treatment. In a recent study, Boston Children's Hospital researchers and colleagues discovered a new driver of resistance, pointing to a way to detect resistant cancer cells early and a possible way to target them.
FDA elevates salad dressing recall to highest risk level over Salmonella concerns as food safety remains under scrutiny.
(MedPage Today) -- Bryce Reynolds, MD, at Carolina Outreach is a paid partner of Teva Pharmaceuticals. One of the biggest paradoxes in schizophrenia care is that some of our most established treatment options are still among the least utilized...
'Insurance companies’ lack of willingness to pay and a lack of resources has led to poor coordination of care and poor treatment options,' writes an L.A. Times reader.
One of the major challenges in treating the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance to treatment. In a recent study, Boston Children's Hospital researchers and colleagues discovered a new driver of resistance, pointing to a way to detect resistant cancer cells early and a possible way to target them.
(MedPage Today) -- Bryce Reynolds, MD, at Carolina Outreach is a paid partner of Teva Pharmaceuticals. One of the biggest paradoxes in schizophrenia care is that some of our most established treatment options are still among the least utilized...